VRHI Veri MedTech Holdings, Inc.

Executive Summary

Veri MedTech Holdings (VRHI) filed Amendment No. 5 to its S-1 IPO registration statement, maintaining the same terms as the prior amendment: a firm commitment offering of 3,750,000 shares at $4.00/share for gross proceeds of $15 million ($13.35M net). The company continues to experience declining revenue (~35% YoY in FY2025 to ~$10.8M, -26% in Q1 2026 to ~$2.4M), net losses, negative equity, and an auditor-identified going-concern risk that the IPO must resolve. The $4.00 offering price represents a ~400% premium to the recent OTC closing price of $1.00/share, and the filing discloses substantial doubt about the company's ability to continue as a going concern without the IPO proceeds.

Actionable Insight

Key Facts

• IPO offering: 3,750,000 shares at $4.00/share for $15M gross / ~$13.35M net proceeds
• FY2025 revenue declined ~35% YoY to ~$10.8M from ~$16.7M; net loss widened to ~$2.32M from ~$0.41M
• Q1 2026 revenue declined ~26% YoY to ~$2.4M from ~$3.3M; net loss ~$200K vs ~$74K
• Going-concern opinion: auditors raised substantial doubt; company had ~$52.8K cash, ~$2.3M current liabilities, and ~$2.4M stockholders' deficit as of March 31, 2026
• Offering price of $4.00 represents ~400% premium to the $1.00 recent OTC close (as of June 9, 2026)
• Insiders hold 100 shares of Series A Preferred with 80% voting control pre- and post-offering
• NASDAQ listing application is a condition to closing; if not approved, the offering will be terminated

Financial Impact

IPO gross proceeds of $15M ($13.35M net) critical to solvency; if successful, eliminates near-term going-concern risk but heavily dilutes existing holders (dilution of $3.54/share to new investors, or 88.5%)

Risk Factors

• Going-concern risk: company may not survive if IPO fails or is delayed; only ~$52.8K cash on hand as of March 31, 2026
• Massive 400% premium to recent OTC price ($4.00 offering vs $1.00 market price) creates substantial downside risk for IPO buyers if secondary market trades closer to OTC levels
• Revenue continues to decline sharply (FY2025 -35%, Q1 2026 -26%) in core medical cannabis card business; regulatory headwinds in key states (FL, AZ, CO) may persist
• Controlled company structure: founders hold 80% voting power via Series A Preferred, limiting minority shareholder influence
• Heavy dilution to existing holders: 3.75M new shares vs 20M outstanding (~18.8% increase); new investors see $3.54/share dilution

Market Snapshot

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

US Market Status